Jazz Pharmaceuticals skids after FDA requests more info for its Luvox drug
Shares of Jazz Pharmaceuticals Inc. (Nasdaq: JAZZ) are sliding today after the drug maker said late Friday that the Food and Drug Administration asked for more information on its drug Luvox CR for the treatment of anxiety disorders.
Jazz, along with its Belgian partner Solvay Pharmaceuticals Inc., is seeking marketing approval for Luvox to treat social anxiety disorder and obsessive compulsive disorder.
On Thursday, the FDA approved the drug for the treatment of OCD.
In January, Jazz licensed the right from Solvay to market Luvox CR and Luvox in the United States.
Shares of Jazz Pharmaceuticals (JAZZ) lost 9.9%, or $1.53, to $13.95 at 12:28 pm. ET. Shares of Jazz Pharmaceuticals have been trading in the range of $11.20 to $18.00 for the past 52 weeks.
